Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The effects of teriparatide on bone microarchitecture as determined by high resolution magnetic resonance imaging and digital topological analysis.

Next Previous
X
Search
Trial Profile

The effects of teriparatide on bone microarchitecture as determined by high resolution magnetic resonance imaging and digital topological analysis.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Oct 2017

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teriparatide (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Eli Lilly and Company

    • Most Recent Events

    • 19 Sep 2011 Results presented at the 33rd Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2011), according to an Eli Lilly media release.
    • 23 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Jun 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top